Predictors of remission of hyperprolactinaemia after long‐term withdrawal of cabergoline therapy

Background  Remission rates of 76, 69·5 and 64·3% have been reported in patients with nontumoural hyperprolactinaemia (NTH), microprolactinoma and macroprolactinoma, respectively, 2–5 years after cabergoline (CAB) withdrawal.

[1]  A. Colao,et al.  Advances in the treatment of prolactinomas. , 2006, Endocrine reviews.

[2]  A. Colao,et al.  The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males , 2006, Clinical endocrinology.

[3]  P. McEwan,et al.  Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. , 2004, Clinical endocrinology.

[4]  A. Colao,et al.  PRL Secreting Adenomas in Male Patients , 2005, Pituitary.

[5]  P. Cappabianca,et al.  Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. , 2004, The Journal of clinical endocrinology and metabolism.

[6]  G. Vitale,et al.  Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. , 2004, The Journal of clinical endocrinology and metabolism.

[7]  G. Krassas,et al.  Cabergoline as a First-Line Treatment in Newly Diagnosed Macroprolactinomas , 2000, Pituitary.

[8]  P. Cappabianca,et al.  Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. , 2004, The New England journal of medicine.

[9]  P. Cappabianca,et al.  Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia , 2003 .

[10]  S. Corsello,et al.  Giant prolactinomas in men: efficacy of cabergoline treatment , 2003, Clinical endocrinology.

[11]  P. Cappabianca,et al.  Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. , 2003, European journal of endocrinology.

[12]  M. Bronstein,et al.  Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. , 2002, The Journal of clinical endocrinology and metabolism.

[13]  M. Losa,et al.  Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. , 2002, The Journal of clinical endocrinology and metabolism.

[14]  P. Cappabianca,et al.  Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. , 2001, The Journal of clinical endocrinology and metabolism.

[15]  J. Wass,et al.  The effect of the menopause on prolactin levels in patients with hyperprolactinaemia , 2001, Clinical endocrinology.

[16]  D. Pauler,et al.  Primary medical therapy of micro- and macroprolactinomas in men. , 2000, The Journal of clinical endocrinology and metabolism.

[17]  P. Marzullo,et al.  The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas , 2000, Clinical endocrinology.

[18]  P. Cappabianca,et al.  Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. , 2000, The Journal of clinical endocrinology and metabolism.

[19]  C. Raftopoulos,et al.  Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients , 2000 .

[20]  C. Raftopoulos,et al.  Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. , 1999, The Journal of clinical endocrinology and metabolism.

[21]  F. Trimarchi,et al.  Cabergoline: A first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma , 1999, Journal of endocrinological investigation.

[22]  G. Brabant,et al.  Treatment of macroprolactinoma with cabergoline: a study of 85 patients. , 1998, Clinical endocrinology.

[23]  M. Cataldi,et al.  Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. , 1997, The Journal of clinical endocrinology and metabolism.

[24]  M. Arosio,et al.  Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients , 1997, Journal of endocrinological investigation.

[25]  J. Donckier,et al.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. , 1997, The Journal of clinical endocrinology and metabolism.

[26]  A. Colao,et al.  Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. , 1997, The Journal of clinical endocrinology and metabolism.

[27]  M. Vance,et al.  Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. , 1996, Journal of Clinical Endocrinology and Metabolism.

[28]  J. Donckier,et al.  Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. , 1996, European journal of endocrinology.

[29]  J. Webster,et al.  A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea , 1994, The New England journal of medicine.

[30]  P. Maggioni,et al.  Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. , 1992, European journal of obstetrics, gynecology, and reproductive biology.

[31]  R. Croughs,et al.  Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. , 1991, Clinical endocrinology.

[32]  R. Croughs,et al.  Withdrawal of bromocriptine after long‐term therapy for macroprolactinomas; effect on plasma prolactin and tumour size , 1991 .

[33]  B. Sherman,et al.  The natural history of untreated hyperprolactinemia: a prospective analysis. , 1989, The Journal of clinical endocrinology and metabolism.

[34]  M. Liu,et al.  LONG‐TERM TREATMENT OF HYPERPROLACTINAEMIA WITH BROMOCRIPTINE: EFFECT OF DRUG WITHDRAWAL , 1987, Clinical endocrinology.

[35]  J. Sheehan,et al.  The natural history of untreated microprolactinomas. , 1987, Fertility and sterility.

[36]  M. Esiri,et al.  FACTORS IN THE OUTCOME OF TRANSSPHENOIDAL SURGERY FOR PROLACTINOMA AND NON‐FUNCTIONING PITUITARY TUMOUR, INCLUDING PREOPERATIVE BROMOCRIPTINE THERAPY , 1987, Clinical endocrinology.

[37]  B. Sherman,et al.  Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors. , 1986, The Journal of clinical endocrinology and metabolism.

[38]  G. Faglia,et al.  Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. , 1985, The Journal of clinical endocrinology and metabolism.

[39]  D. Cook,et al.  EFFECT OF DOPAMINE AGONIST WITHDRAWAL AFTER LONG-TERM THERAPY IN PROLACTINOMAS Studies with High-definition Computerised Tomography , 1984, The Lancet.

[40]  M. Dudzinski,et al.  Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. , 1984, Fertility and sterility.

[41]  D. Cook,et al.  Hyperprolactinemia. Long-term effects of bromocriptine. , 1983, The American journal of medicine.

[42]  A. Zarate,et al.  Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. , 1983, Acta endocrinologica.

[43]  L. Wide,et al.  MENSTRUAL FUNCTION AND SERUM PROLACTIN LEVELS AFTER LONG‐TERM BROMOCRIPTINE TREATMENT OF HYPERPROLACTINAEMIC AMENORRHOEA , 1982, Clinical endocrinology.